Day: 2026年3月5日

West Palm Beach, FL, Mar 5, 2026 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly announces the continued expansion of its Collegiate Partnership Program (CPP) for the 2026 season and academic year. Now in its eighth consecutive year, the program reaches a historic milestone by supporting 70 collegiate teams across 31 universities nationwide, the largest number of teams ever participating in the program.U.S. Polo Assn.'s Collegiate Partnership Program featuring the California Polytechnic State University Women's and Men's Polo TeamsPhoto Credit: California Polytechnic State University Polo TeamsU.S. Polo Assn. will outfit hundreds of student-athletes from coast to coast, including small private and large public institutions, Ivy League Universities, and Historically Black Colleges and Universities (HBCUs). The CPP supports 35 women's and 35 men's teams, reinforcing U.S. Polo Assn.'s long-standing commitment to growing the sport at the collegiate level. This season welcomes two new schools, Babson University and Southern Methodist University, joining a distinguished group of institutions nationwide.This year, U.S. Polo Assn. will generously provide each partnered program with custom-performance team jerseys, white performance game pants, polo shirts, caps, equipment gear bags, and exclusive USPA Pro merchandise, along with a monetary donation. The program also continues its popular collegiate social media contest, where teams have the opportunity to win additional prizes through creative digital engagement and storytelling.Participating Schools Include:Babson UniversityMorehouse CollegeTrinity UniversityUniversity of North TexasBrown UniversityOklahoma State UniversityUniversity of California - DavisUniversity of Southern CaliforniaCalifornia Polytechnic State UniversityOregon State UniversityUniversity of ConnecticutUniversity of South Carolina - AikenColorado State UniversitySkidmore CollegeUniversity of IdahoUniversity of VirginiaCornell UniversitySouthern Methodist UniversityUniversity of KentuckyUniversity of Wisconsin - MadisonGeorgetown UniversityStanford UniversityUniversity of MarylandVirginia Tech UniversityMichigan State UniversityTexas A&M UniversityUniversity of MichiganYale UniversityMontana State UniversityTexas Tech UniversityUniversity of New Hampshire "U.S. Polo Assn. is proud to support a record number of collegiate polo teams and student-athletes through the Collegiate Partnership Program," said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar U.S. Polo Assn. brand. "This critical program strengthens the foundation of the sport by providing meaningful resources to collegiate polo programs across the country. Supporting 70 teams this season reflects both the growth of the program and our long-term commitment to supporting the next generation of players both on and off the polo field."Enrollment for U.S. Polo Assn.'s Collegiate Partnership Program is open to all colleges and universities with a USPA-sanctioned polo team and lasts for the academic year. Collegiate polo teams compete in the Fall and Spring, with the official season running through April 2026 and culminating in the National Intercollegiate Championship (NIC)."Our partnership with U.S. Polo Assn. for the last eight years continues to make a meaningful difference for collegiate programs nationwide," said Liz Brayboy, Chair of the USPA's Intercollegiate/Interscholastic Committee. "The support provided through the Collegiate Partnership Program helps teams build stronger programs, develop student-athletes, and showcase the spirit and sportsmanship that define collegiate polo."The two-time award-winning series Breakaway, created by Global Polo, the media subsidiary of USPA Global, will feature a new episode in its upcoming season. Titled "Breakaway: Polo in College," the episode will air later this year on ESPNU, offering national exposure to the excitement and impact of collegiate polo. Check your local listings for air times.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and located in Wellington, Florida. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.For Additional Information, Contact:Shannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.comStacey Kovalsky - VP, Global PR and CommunicationsPhone +001.561.790.8036 - E-mail: skovalsky@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛罗里达州西棕榈滩, 2026年3月5日 - (亚太商讯 via SeaPRwire.com) - 美国马球协会（USPA）官方运动品牌U.S. Polo Assn.今日宣布，其大学合作计划（CPP）将在2026赛季及学年持续扩大规模。该计划已连续第八年实施，本季将支持全美31所高校的70支校队，创历史新高，成为参与规模最大的一届。U.S. Polo Assn.'s Collegiate Partnership Program featuring the California Polytechnic State University Women's and Men's Polo TeamsPhoto Credit: California Polytechnic State University Polo Teams美国马球协会将为遍布东西海岸的数百名学生运动员提供装备，涵盖小型私立院校、大型公立大学、常春藤盟校及历史悠久的黑人学院与大学（HBCUs）。该计划同时支持35支女子队与35支男子队，彰显美国马球协会长期致力于推动大学马球运动发展的承诺。本赛季新增巴布森学院与南卫理公会大学两所成员院校，加入全国顶尖高校行列。本年度，美国马球协会将慷慨为每支合作队伍提供定制高性能队服、白色比赛长裤、马球衫、运动帽、装备包及独家USPA Pro商品，并追加现金捐赠。该计划还将延续广受欢迎的高校社交媒体竞赛，各队可通过创意数字互动与故事讲述赢取额外奖品。参与院校包括：Babson UniversityMorehouse CollegeTrinity UniversityUniversity of North TexasBrown UniversityOklahoma State UniversityUniversity of California - DavisUniversity of Southern CaliforniaCalifornia Polytechnic State UniversityOregon State UniversityUniversity of ConnecticutUniversity of South Carolina - AikenColorado State UniversitySkidmore CollegeUniversity of IdahoUniversity of VirginiaCornell UniversitySouthern Methodist UniversityUniversity of KentuckyUniversity of Wisconsin - MadisonGeorgetown UniversityStanford UniversityUniversity of MarylandVirginia Tech UniversityMichigan State UniversityTexas A&M UniversityUniversity of MichiganYale UniversityMontana State UniversityTexas Tech UniversityUniversity of New Hampshire “美国马球协会很荣幸通过大学合作计划支持创纪录数量的校队及学生运动员，”管理着价值数十亿美元美国马球协会品牌的USPA Global总裁兼首席执行官J·迈克尔·普林斯表示，"该关键计划通过为全国大学马球项目提供实质性资源，巩固了这项运动的基础。本赛季支持70支队伍的规模，既体现项目发展壮大，也彰显我们长期致力于培养新一代球员——无论在马球场内外。"美国马球协会大学合作计划面向所有拥有USPA认证马球队伍的高校开放，合作周期为整个学年。大学马球队伍在秋季和春季参赛，正式赛季将持续至2026年4月，最终决战全国大学锦标赛（NIC）。“过去八年来，我们与美国马球协会的合作持续为全国高校项目带来深远影响，”美国马球协会校际委员会主席莉兹·布雷博伊表示，“该合作计划提供的支持助力各校建立更完善的项目体系，培养学生运动员，并彰显定义大学马球运动的竞技精神与体育风范。”由USPA全球媒体子公司Global Polo制作的获奖系列纪录片《突破》即将推出新季。题为《突破：大学马球》的专题片将于今年晚些时候在ESPNU频道播出，向全国观众展现大学马球的激情与影响力。具体播出时间请查阅当地节目表。关于美国马球协会及USPA Global美国马球协会（USPA）是美国规模最大的马球俱乐部及球员组织，创立于1890年，总部位于佛罗里达州惠灵顿市。其官方运动品牌“美国马球协会”（U.S. Polo Assn.）由此诞生。该品牌全球业务规模达数十亿美元，通过1200余家美国马球协会专卖店及数千个分销点覆盖全球，为190多个国家的男女儿童提供服饰、配饰及鞋履产品。该品牌赞助全球多项顶级马球赛事，包括每年在棕榈滩国家马球俱乐部举办的美国公开马球锦标赛®——美国最高规格的马球赛事。通过与美国ESPN、欧洲TNT及Eurosport、印度Star Sports等媒体达成的历史性合作，全球数百万体育爱好者首次得以通过电视转播观赏由美国马球协会赞助的顶级马球锦标赛。For Additional Information, Contact:Shannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.comStacey Kovalsky - VP, Global PR and CommunicationsPhone +001.561.790.8036 - E-mail: skovalsky@uspagl.comSOURCE: U.S. Polo Assn. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 5, 2026) - Lancaster Resources Inc. (CSE: LCR) (OTC Pink: LANRF) (FSE: 6UF0) ("Lancaster" or the "Company") announces the director resignation of Penny White, effective March 3, 2026. The Board thanks Penny White for her valuable contributions during her tenure and wishes her continued success in her future endeavors.The Company is also pleased to announce the appointment of Mr. Rob Heaslop, as a director to the company's Board of Directors, effective immediately.Mr. Heaslop is a geologist with 20 years' of exploration and resource development experience in Africa, Australia, and the Pacific with specific expertise in project generation and early stage targeting for precious and base metal deposits. Mr. Heaslop holds a Bachelor of Science (Hons) from The University of Queensland majoring in earth science and geology, and during his career has worked for major, junior, and private exploration and mining companies. In 2016, Mr. Heaslop founded his privately owned project generation company, MRG Resources Pty Ltd, that has created significant value identifying exploration opportunities in Australia, including deals with major and mid-tier mining houses and private exploration companies. Mr. Heaslop is a member of the Australasian Institute of Mining and Metallurgy (MAusIMM), Australian Institute of Geoscientists (MAIG), and the Society of Economic Geologists (SEG)."We are thrilled to welcome Mr. Heaslop to the Board," said Andrew Watson, President & CEO of Lancaster Resources. "His technical expertise will be invaluable as Lancaster continues to develop our Lake Cargelligo gold project, Lac Iris polymetallic asset, and our other critical and precious mineral assets."Rob Heaslop commented, "I am focused on the opportunities ahead and committed to help navigate a successful exploration program for our projects and shareholders. I am truly excited to continue working with the team here."The new board appointment reflects Lancaster Resources' transition to a new corporate direction and commitment to strengthening its leadership and strategic capabilities to enhance shareholder value and propel the company's growth in the mining industry.Andrew Watson, P.Eng., President & CEO and a Director of the Company, is a Qualified Person as defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Mr. Watson has reviewed and approved the scientific and technical information contained in this news release. Mr. Watson is a Director and the President and CEO of Lancaster and is not independent of the Company.About Lancaster Resources Inc. Lancaster Resources Inc. is a Canadian exploration company advancing a diversified portfolio of gold and silver exploration projects in established mining jurisdictions. The Company holds a 100% interest in the Lake Cargelligo Gold Project in New South Wales, Australia, which is prospective for both gold and silver mineralization, covering approximately 62,300 hectares with a history of drilling and exploration and multiple high-priority targets. In Canada, Lancaster's assets include the Lac Iris Polymetallic Project in Quebec's James Bay region and the Piney Lake Gold Project in Saskatchewan. Lancaster's portfolio provides exposure to gold, silver, and polymetallic exploration opportunities across tier-one jurisdictions.Andrew Watson, President & Chief Executive Officer,Lancaster Resources Inc.Andrew@Lancaster-Resources.comTel: (604) 923-6100www.lancaster-resources.comThe Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release. Cautionary Statement Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events, or Lancaster's future performance. The use of any of the words "could", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Lancaster's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, the ability of Lancaster to execute its exploration plans, raise capital, retain key personnel, identify, acquire, explore, and develop high-quality mineral-rich properties constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. Lancaster disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286260 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, CHINA, Mar 5, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals.About CMS-D008CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases.Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles.CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solutionCMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options.The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564.2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=233. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年3月5日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司（“康哲药业”）欣然宣布，其自主研发的创新药INHBE小核酸药物CMS-D008注射液（“CMS-D008”）于2026年3月4日获得中国国家药品监督管理局（“NMPA”）签发的药物临床试验批准通知书。NMPA同意开展CMS-D008注射液用于超重或肥胖的临床试验。关于CMS-D008CMS-D008是一款皮下注射的siRNA药物，靶向抑制肝脏的抑制素亚基βE（INHBE）基因表达，下调INHBE编码蛋白激活素E（Activin E）水平，从而降低脂肪代谢通路Activin E-ALK7的活化，有效减少脂质堆积。临床前研究提示CMS-D008高效持续抑制INHBE表达，肥胖动物模型中，在不影响肌肉的情况下，获得明显的减重减脂效果，且安全性良好；显示减脂不减肌，长期高质量减重的良好前景。未来可开发治疗超重/肥胖，腹型肥胖以及相关代谢性疾病。减脂不减肌，超重/肥胖的潜在更优治疗方案超重或肥胖是一种脂肪组织过度积累或分布、功能异常的慢性、进行性、复发性疾病[1]。根据《2025年世界肥胖报告》，预测到2030年，全球超重和肥胖成年人的比例会上升到50%，将有近30亿成年人受到高体重指数（BMI）的影响，我国成人超重/肥胖人数将达到5.15亿[2]。现有的GLP-1RA类药物显示了很好的减重效果，该类药物主要通过作用于中枢神经系统抑制食欲，延缓胃排空来降低体重[3]，而INHBE不同于GLP-1类药物的作用机制，是从全基因组关联分析筛选获得，INHBE功能丧失的人群拥有良好的体脂分布和有利的代谢特征[4]，靶向抑制INHBE可以从基因水平精准减少内脏脂肪，改善代谢状态，更有利于长期体重管理。 CMS-D008携手CMS-D005：高效减重与长期维持联合发力，构建更全面减重方案CMS-D008将与正处于临床开发阶段的自研创新药CMS-D005形成协同，CMS-D008通过精准抑制INHBE基因表达，减脂不减肌；而CMS-D005作为GLP-1R/GCGR双重激动剂，可在减重同时，强效降低肝脏脂肪，二者协同实现高效的减重获益与长期的成果维持，共同增强康哲药业在肥胖/代谢治疗领域的研发实力与产品竞争力，并依托其在心血管代谢疾病领域成熟的网络资源，加速药物的研发与商业化进程，为患者提供更全面、创新的治疗方案。康哲药业正积极准备开展相关临床试验工作，力争该产品尽快上市。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心肾代谢/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1.中华医学会内分泌学分会. 肥胖患者的长期体重管理及药物临床应用指南(2024版).中华内分泌代谢杂志,2024,40(7):545-564.2.世界肥胖联盟. 《2025 年世界肥胖报告》[EB/OL]. 伦敦：世界肥胖联盟，2025. https://data.worldobesity.org/publications/?cat=233.Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z4.Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7.康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和-医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 5, 2026 - (ACN Newswire via SeaPRwire.com) - Core Concepts Physio, one of Singapore's leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain.Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved.To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked.A Smarter, More Complete Way to Diagnose Heel PainPhysiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support.The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in:More accurate, holistic diagnosesFully optimised treatment strategiesFewer flare-ups and recurrencesClearer, consistent guidance for patientsFaster and more sustainable outcomes"Many patients struggle because plantar fasciitis isn't caused by just one issue," said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. "It's a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms."A Case Study Demonstrating Collaborative SuccessIn a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts.A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient's daily load decreased significantly — allowing physiotherapy progress to continue without setbacks.Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running."This case reflects what we see frequently," said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. "Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery."Making Multidisciplinary Care Accessible NationwideThrough this collaboration, patients with plantar fasciitis now benefit from:Joint physiotherapy–podiatry assessmentsAligned clinical decision-makingConsistent communication across providersA thorough evaluation of both the cause and consequence of heel painA fully optimised recovery pathway"Our multidisciplinary team brings together the best of both professions," said Mr Chng Chye Tuan. "Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands."About Core Concepts PhysiotherapyCore Concepts Physio is one of Singapore's largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580.About Podiatry QuestPodiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care.Contact DetailsOrganization: Core Concepts Pte LtdContact: Clemence LimWebsite: https://www.coreconceptsphysio.sg Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com